<?xml version='1.0' encoding='utf-8'?>
<document id="31787689"><sentence text="[Pharmacological, pharmacodynamics, and clinical profile of mirogabalin besylate (Tarlige® tablets 2.5 mg∙5 mg∙10 mg∙15 mg)]."><entity charOffset="60-80" id="DDI-PubMed.31787689.s1.e0" text="mirogabalin besylate" /></sentence><sentence text="Mirogabalin, a novel ligand for the α2δ subunit of voltage-gated calcium channels, has been approved for the treatment of peripheral neuropathic pain including painful diabetic peripheral neuropathy (DPNP) and postherpetic neuralgia (PHN) in Japan"><entity charOffset="0-11" id="DDI-PubMed.31787689.s2.e0" text="Mirogabalin" /><entity charOffset="65-72" id="DDI-PubMed.31787689.s2.e1" text="calcium" /><pair ddi="false" e1="DDI-PubMed.31787689.s2.e0" e2="DDI-PubMed.31787689.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31787689.s2.e0" e2="DDI-PubMed.31787689.s2.e1" /></sentence><sentence text=" Mirogabalin showed potent and selective binding affinities for the α2δ subunits, and slower dissociation rates for the α2δ-1 subunit than for the α2δ-2 subunit"><entity charOffset="1-12" id="DDI-PubMed.31787689.s3.e0" text="Mirogabalin" /></sentence><sentence text=" It also showed potent and long-lasting analgesic effects in rat models of neuropathic pain, and wider safety margins for the central nervous system side effects" /><sentence text=" A pharmacological study using mutant mice demonstrated that the analgesic effects of mirogabalin were mediated by binding of the drug to the α2δ-1 subunit, not the α2δ-2 subunit"><entity charOffset="86-97" id="DDI-PubMed.31787689.s5.e0" text="mirogabalin" /></sentence><sentence text=" The pharmacological properties of mirogabalin can be associated with its unique binding characteristics"><entity charOffset="35-46" id="DDI-PubMed.31787689.s6.e0" text="mirogabalin" /></sentence><sentence text=" The bioavailability of mirogabalin is high and its plasma exposure increases dose-proportionally"><entity charOffset="24-35" id="DDI-PubMed.31787689.s7.e0" text="mirogabalin" /></sentence><sentence text=" Mirogabalin is mainly excreted via the kidneys in an unchanged form, thus, mirogabalin has a low possibility of undergoing drug-drug interaction, while dose adjustment based on the creatinine clearance level is specified in patients with renal impairment"><entity charOffset="1-12" id="DDI-PubMed.31787689.s8.e0" text="Mirogabalin" /><entity charOffset="76-87" id="DDI-PubMed.31787689.s8.e1" text="mirogabalin" /><entity charOffset="182-192" id="DDI-PubMed.31787689.s8.e2" text="creatinine" /><pair ddi="false" e1="DDI-PubMed.31787689.s8.e0" e2="DDI-PubMed.31787689.s8.e0" /><pair ddi="false" e1="DDI-PubMed.31787689.s8.e0" e2="DDI-PubMed.31787689.s8.e1" /><pair ddi="false" e1="DDI-PubMed.31787689.s8.e0" e2="DDI-PubMed.31787689.s8.e2" /><pair ddi="false" e1="DDI-PubMed.31787689.s8.e1" e2="DDI-PubMed.31787689.s8.e1" /><pair ddi="false" e1="DDI-PubMed.31787689.s8.e1" e2="DDI-PubMed.31787689.s8.e2" /></sentence><sentence text=" In double-blind, placebo-controlled phase 3 studies in Asian patients with DPNP and PHN, mirogabalin showed significant and dose-dependent pain relief, and all tested doses of mirogabalin were well tolerated"><entity charOffset="85-88" id="DDI-PubMed.31787689.s9.e0" text="PHN" /><entity charOffset="90-101" id="DDI-PubMed.31787689.s9.e1" text="mirogabalin" /><entity charOffset="177-188" id="DDI-PubMed.31787689.s9.e2" text="mirogabalin" /><pair ddi="false" e1="DDI-PubMed.31787689.s9.e0" e2="DDI-PubMed.31787689.s9.e0" /><pair ddi="false" e1="DDI-PubMed.31787689.s9.e0" e2="DDI-PubMed.31787689.s9.e1" /><pair ddi="false" e1="DDI-PubMed.31787689.s9.e0" e2="DDI-PubMed.31787689.s9.e2" /><pair ddi="false" e1="DDI-PubMed.31787689.s9.e1" e2="DDI-PubMed.31787689.s9.e1" /><pair ddi="false" e1="DDI-PubMed.31787689.s9.e1" e2="DDI-PubMed.31787689.s9.e2" /></sentence><sentence text=" In summary, mirogabalin has a balanced efficacy versus safety profile, and can provide an alternative therapeutic option for the treatment of peripheral neuropathic pain"><entity charOffset="13-24" id="DDI-PubMed.31787689.s10.e0" text="mirogabalin" /></sentence><sentence text="" /></document>